Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA due to it's high cost and limited access. NBC News' Yamiche Alcindor spoke ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

New Delhi, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.26 billion by 2033 at a CAGR ...

AMT-162 is under clinical development by UniQure and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 51% phase ...

GEMMA Biotherapeutics, the start-up that gene therapy pioneer Jim Wilson founded earlier this year, has raised $34 million in ...

From 2018 to 2022, the migraine treatments market grew at a CAGR of 3%. The global migraine treatments market is expected to ...

Qure (NASDAQ:QURE – Get Free Report) shares were up 5.8% during mid-day trading on Friday after Mizuho raised their price ...

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 ...